(NASDAQ: MRNA) Moderna's forecast annual revenue growth rate of 6.34% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.88%.
Moderna's revenue in 2025 is $3,177,000,000.On average, 10 Wall Street analysts forecast MRNA's revenue for 2025 to be $828,965,621,497, with the lowest MRNA revenue forecast at $773,135,572,362, and the highest MRNA revenue forecast at $944,268,827,712. On average, 10 Wall Street analysts forecast MRNA's revenue for 2026 to be $1,118,735,024,067, with the lowest MRNA revenue forecast at $749,914,433,264, and the highest MRNA revenue forecast at $2,079,820,159,596.
In 2027, MRNA is forecast to generate $1,494,763,322,169 in revenue, with the lowest revenue forecast at $1,040,702,127,045 and the highest revenue forecast at $3,101,630,722,218.